A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Allegheny Health Network, Allegheny General Hospital, Cleveland Clinic, Abramson Cancer Center, Massachusetts General Hospital, The University of Texas Southwestern Medical Center, Comprehensive Cancer Centers of Nevada, Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4324136252